Digital Therapeutics Explained: Software That Works Like Medicine

• Digital therapeutics are software products that deliver evidence based therapeutic interventions and are authorized to prevent, manage or treat a defined disease state.
• Regulators classify them as software functioning as a medical device, which places them under the same oversight as physical devices.
• Clinical evidence comes from randomized trials and systematic reviews published in peer-reviewed journals, not from user ratings.
• Mental health, substance abuse and metabolic conditions account for most authorized products so far.
• Reimbursement remains the narrow point, although Germany and the United States have both built payment pathways.
• Aegis Capital invests in early-stage HealthTech & Longevity companies, including digital therapy, with an initial ticket of up to PLN 3 million.

What are digital therapeutics?

Digital therapeutics are software-driven interventions, validated in clinical studies, that prevent, manage or treat a medical condition. The software itself is the therapy, which is what separates it from a tool that supports a therapy delivered by something else. According to the definition used by regulators and by the scientific literature, the product must state what it treats and show that it works. A product in this category has a defined indication, a defined mechanism and clinical data behind both. That is the whole of DTx as a category, and anything outside it belongs to wellness.

The category covers a broad spectrum of physical and behavioral conditions, from insomnia and depression through type 2 diabetes to chronic pain. The result is a set of treatments for patients that are driven by high quality software programs rather than by molecules. Aegis Capital counts digital therapy and mental health among the five areas it invests in, alongside AI and digital health, diagnostics, nutritech and human improvement.

Digital therapeutics DTx and the boundary with health apps

The abbreviation DTx marks the line between clinical software and consumer wellness. Anyone can publish a meditation or step-counting app; nobody can publish a digital therapeutic without regulatory authorization and evidence to support the claim. Three differences define the boundary:

• Wellness apps make general wellbeing claims, while DTx products state a specific indication.
• Wellness apps are not reviewed by a regulator before launch, while DTx products need clearance or certification.
• Wellness apps rely on engagement data, while DTx products rely on outcome data from controlled studies, for example a randomized trial against usual care.

The distinction has practical consequences. A physician can prescribe a digital therapeutic and document it in a treatment plan, and a payer can reimburse it. Neither happens with an app that has never been assessed against a clinical endpoint.

Clinical evidence and the regulatory status of digital health products

Evidence for digital health interventions is published in the same venues as evidence for drugs and devices. Randomized trials of digital cognitive behavioral therapy have appeared in journals including The Lancet Psychiatry, and systematic review articles covering app-based interventions appear regularly in JMIR Mental Health and in JMIR mHealth and uHealth. Trial quality varies, and a systematic review is the sensible starting point for anyone assessing a claim.

One common assumption deserves correcting. Digital therapeutics are frequently described as requiring three phases of clinical trials, borrowing the framework used for pharmaceuticals. Software follows the device pathway instead: a randomized controlled trial is the usual basis for an efficacy claim, however the number and design of studies depends on risk class and on whether the manufacturer relies on a predicate device.

Regulation: when software becomes a medical device

Software becomes a medical device when its intended purpose is diagnosis, prevention, monitoring, prediction, prognosis or treatment. In the United States, the FDA regulates digital therapeutics as Software as a Medical Device, and several products have reached the market through 510(k) clearance or the De Novo route. In the European Union, Regulation 2017/745 classifies medical devices by risk and intended use, and its rules on software push most therapeutic applications above the lowest risk class.

Rules differ between jurisdictions, and they differ within the European Union as well, because market access is harmonized while reimbursement stays national. As such, a product certified once under EU rules still faces a separate negotiation in every country where it wants to be paid for.

The path from clearance to reimbursement

Clearance proves that a product may be sold. Payment is a separate process for which manufacturers often underestimate the timeline and the cost. Germany moved first: the Digital Healthcare Act, in force since 2020, created a listing that allows physicians to prescribe approved digital health apps at the expense of statutory insurance.

The United States followed with a payment mechanism rather than a coding change. Contrary to a claim that circulates in industry summaries, CMS did not introduce new CPT codes for DTx, since CPT codes are maintained by the American Medical Association. What CMS established in the 2025 Physician Fee Schedule were three HCPCS codes, G0552 to G0554, covering the supply of a digital mental health treatment device and the treatment management that follows. Devices must hold FDA clearance or De Novo authorization to qualify.

How the mechanism of digital therapeutics works

The therapeutic effect of digital therapeutics comes from structured behavioral and cognitive intervention delivered on a schedule, not from a chemical acting on a receptor. A program breaks an evidence based protocol into daily tasks, adapts them to the response of the patient, and records what happens. Three mechanisms carry most of the effect:

• Cognitive behavioral therapy delivered algorithmically, which targets the thought patterns that maintain a condition.
• Personalized stimuli and prompts, which support active management of a chronic disease.
• Continuous data capture from the patient and from connected devices, which shows clinicians whether the protocol is working. The use of wearables and connected meters turns a self-report into a measurement that can be verified.

Did you know: digital cognitive behavioral therapy for insomnia is one of the most extensively studied interventions in the field, with efficacy data that in several trials matched face-to-face delivery. Repetition is the mechanism, and completion of the protocol predicts outcome more reliably than any single feature of the interface.

Digital therapeutics in mental health

Mental health accounts for the largest share of authorized products, for two reasons: cognitive behavioral therapy is protocol-driven and therefore translates well into software, and access to therapists is limited almost everywhere. Programs for depression, anxiety and insomnia guide the patient through the same exercises a clinician would assign, at a pace the patient sets. Trials show them to be effective in mild to moderate cases, and additional studies are testing them in more severe presentations.

Access is the practical benefit. A patient waiting months for an appointment can begin a validated protocol immediately, and clinicians get the data they need to adjust the plan at the next visit. Improvement in health outcomes still depends on completion, which is why adherence design receives as much attention as clinical content. A protocol that can be abandoned in week two will not help anyone, whatever its trial results say.

Substance abuse and other behavioral indications

Substance abuse was among the first indications where a prescription digital therapeutic reached the market in the United States, using contingency management and cognitive behavioral techniques. ADHD and post-traumatic stress disorder have followed, with authorized products in each area.

A caveat belongs here. These programs rarely replace established treatments outright, and the claim that digital therapies can substitute for therapies used for the past twenty or thirty years overstates the evidence. In most indications the data supports use either as a standalone intervention in mild cases or as an addition to medication or other therapies.

Examples of validated programs and where they are used

Beyond behavioral health, the strongest evidence sits in metabolic and respiratory disease. Programs for type 2 diabetes combine glucose data from connected meters with diet and activity coaching, and their clinical case rests on measurable change in glycemic control rather than on engagement. Similar logic applies in cardiology and pulmonology, where a program can reduce unplanned hospital visits by catching deterioration early.

Example: one certified digital therapeutics device for oncology patients, developed by a company our team backed through an earlier fund, delivers structured psychological support that reduces stress, anxiety and depression symptoms at different stages of cancer treatment. The product illustrates the pattern that defines the category: a specific population, a defined endpoint and clinical data supporting the claim.

Tip: before you rely on any program, check whether it names a regulator, a clearance or certification, and a published trial. If a product cannot point to all three, treat it as a wellness tool.

Funding the development of digital therapeutics

Building a digital therapeutic costs more than building an app, because trials, quality management systems and post-market surveillance are part of the model rather than an afterthought. That cost profile is why the category depends on investors who understand regulated products and can price a clinical timeline.

Market estimates for digital therapeutics vary widely by provider, which is worth knowing before quoting a single number. Global Market Insights valued the market at USD 7.7 billion in 2024, Emergen Research put it at USD 8.74 billion in 2025, and Fortune Business Insights at USD 10.15 billion for the same year. All three project double-digit growth, and the range between them reflects different definitions of what counts inside the category.

Aegis Capital invests at pre-seed and seed stage in Central and Eastern Europe, with digital therapy and mental health among its focus areas. The fund provides an initial ticket of up to PLN 3 million, total funding of up to PLN 8 million per company including follow-on rounds, and access to clinicians and operators who have taken certified products to market.

Frequently asked questions

Are digital therapeutics available on prescription?

Yes, in several markets. Prescription digital therapeutics are ordered by a physician in the same way as a drug or a device, and in Germany and the United States there are mechanisms for statutory or Medicare payment. Products outside those pathways may still be available directly to patients, who can learn more about a specific program from the manufacturer or from the physician treating them.

Do digital therapeutics replace medication?

Not usually. Depending on the indication, a digital therapeutic can be used either as a standalone treatment in milder cases or as an addition to pharmacotherapy, and the labeling states which applies. Any claim of a general substitute for drug treatment goes beyond the current evidence.

How is a digital therapeutic different from a health app?

A digital therapeutic has a regulatory status, a defined indication and clinical data; a health app has none of those requirements. The difference is not the interface but the level of proof required before the product can make a treatment claim.

What conditions do DTx products address?

Authorized products address depression, anxiety, insomnia, ADHD, substance abuse, type 2 diabetes, chronic pain and several respiratory conditions. The range of indications keeps widening as more trials read out.

Who pays for digital therapeutics in Europe?

Payment is decided nationally. Germany reimburses listed digital health applications through statutory insurance, France has built its own access route, and in many other countries there is no established mechanism, which leaves patients paying privately or gaining access through a hospital program.

‍